Photocure ASA (PHO.OL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Daniel Schneider | President & CEO | -- | -- | -- |
| Mr. Erik Dahl | Chief Financial Officer | -- | -- | 1957 |
| Anja Gossens-von der Heidt | Head of Global Human Resources | -- | -- | -- |
| Dr. Anders Neijber M.D. | Chief Medical Officer of Global Medical Affairs, Clinical Development and R&D | -- | -- | -- |
| Mr. David Moskowitz | Head of Investor Relations | -- | -- | -- |
| Mr. Tolv Hillestad | Group Controller | -- | -- | -- |
Photocure ASA
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 99
Description
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, rest of the Europe, Canada, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Corporate Governance
Upcoming Events
May 8, 2025 at 6:00 AM UTC
Photocure ASA Earnings Date
Recent Events
May 23, 2013 at 12:00 AM UTC
Ex-Dividend Date